Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies Horwitz, S. M., Foran, J. M., Maris, M., Lue, J., Sawas, A., Okada, C., Feldman, T. A., Sokol, L., Mei, M., Flinn, I. W., Villa, D., Percival, M. M., Jagadeesh, D., Savage, K. J., Akilov, O., Diefenbach, C. S., Kim, Y. H., Lin, G. Y., Catalano, T., Petrova, P. S., Uger, B., Molloy, N., Large, K., Bruns, I., Ansell, S. M. AMER SOC HEMATOLOGY. 2021

View details for DOI 10.1182/blood-2021-154490

View details for Web of Science ID 000736413901178